BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15278306)

  • 1. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography.
    Lee JD; Yun M; Lee JM; Choi Y; Choi YH; Kim JS; Kim SJ; Kim KS; Yang WI; Park YN; Han KH; Lee WJ; Yoo N; Lim SM; Park JH
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1621-30. PubMed ID: 15278306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
    Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
    Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
    J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
    Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
    Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
    Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG kinetics and gene expression in giant cell tumors.
    Strauss LG; Dimitrakopoulou-Strauss A; Koczan D; Bernd L; Haberkorn U; Ewerbeck V; Thiesen HJ
    J Nucl Med; 2004 Sep; 45(9):1528-35. PubMed ID: 15347720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
    Lee M; Ko H; Yun M
    Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro.
    Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Kitamura K; Ikai I; Uemoto S
    Int J Oncol; 2009 May; 34(5):1303-12. PubMed ID: 19360342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma.
    Lin WY; Tsai SC; Hung GU
    Nucl Med Commun; 2005 Apr; 26(4):315-21. PubMed ID: 15753790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Higuchi T; Miyakubo M; Ishikita T; Nakajima T; Endo K
    Ann Nucl Med; 2008 Jan; 22(1):83-6. PubMed ID: 18250992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.
    Zhao S; Kuge Y; Mochizuki T; Takahashi T; Nakada K; Sato M; Takei T; Tamaki N
    J Nucl Med; 2005 Apr; 46(4):675-82. PubMed ID: 15809491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake.
    Lee JD; Yang WI; Park YN; Kim KS; Choi JS; Yun M; Ko D; Kim TS; Cho AE; Kim HM; Han KH; Im SS; Ahn YH; Choi CW; Park JH
    J Nucl Med; 2005 Oct; 46(10):1753-9. PubMed ID: 16204727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma.
    Yun M; Bang SH; Kim JW; Park JY; Kim KS; Lee JD
    J Nucl Med; 2009 Aug; 50(8):1222-8. PubMed ID: 19617323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET Imaging of Hepatocellular Carcinomas:
    Zhao J; Zhang Z; Nie D; Ma H; Yuan G; Su S; Liu S; Liu S; Tang G
    Mol Imaging; 2019; 18():1536012118821032. PubMed ID: 30799682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
    Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
    Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer.
    Chung JK; Lee YJ; Kim SK; Jeong JM; Lee DS; Lee MC
    Nucl Med Commun; 2004 Jan; 25(1):11-7. PubMed ID: 15061260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
    Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M
    J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased 18F-FDG Uptake on PET/CT is Associated With Poor Arterial and Portal Perfusion on Multiphase CT.
    Hwang SH; Lee M; Lee N; Park S; Kim CK; Park MA; Yun M
    Clin Nucl Med; 2016 Apr; 41(4):296-301. PubMed ID: 26756099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor.
    Koyama K; Okamura T; Kawabe J; Ozawa N; Higashiyama S; Ochi H; Yamada R
    Ann Nucl Med; 2002 May; 16(3):169-76. PubMed ID: 12126041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.